FTC Report Finds Pharmacy Benefit Managers Inflate Drug Prices
- The Federal Trade Commission's report reveals that Pharmacy Benefit Managers significantly inflate drug prices, harming patients and independent pharmacies, especially in rural areas, as stated by FTC Chair Lina Khan.
- The FTC plans to sue three large health companies for their roles as middlemen in inflating medication costs, including insulin, according to a source for CNBC.
- The report criticizes the three largest PBMs for manipulating the drug supply chain, ultimately disadvantaging independent pharmacies and increasing costs for patients.
Insights by Ground AI
Does this summary seem wrong?
0 Articles
0 Articles
All
Left
Center
Right
Coverage Details
Total News Sources0
Leaning Left9Leaning Right4Center25Last UpdatedBias Distribution66% Center